Introduction
The progression of disease during or after systemic treatment in solid tumors may be related to both primary and acquired resistance phenomena. The major known mechanisms found in 50% of tumors are p53 [1] and p-glycoprotein [2] mutations, responsible for the multidrug-resistant phenotype.
Recently, the important role of the immune system in growth cell control and neoplastic progression has been identified. The mechanisms triggering the immune escape can be of vascular character for endothelial damage or due to inhibition of immune activation by galectin [3] or CTLA4 ligands [4] [5] [6] [7] . Furthermore, the metabolic damage resulting in amino acid depletion, such as tryptophan and arginine, in the microenvironment due to indoleamine dioxygenase (IDO) [8] [9] [10] and arginase, and the secretion of suppressive mediators, such as in the microenvironment due to indoleamine dioxygenase (IDO) [8] [9] [10] and arginase, and the secretion of suppressive mediators, such as PGE2, TGFb, IL10 and adenosine [11] , disrupt lymphocyte proliferation. Finally, this can be linked to a functional impairment of the immune response through apoptotic depletion by FasL, PD-L1 or PD-L2 [12] [13] [14] [15] [16] [17] . These immunosuppressive mechanisms involve different types of cells such as tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), type 2 natural killer T (NKT) cells [18] , and regulatory T cells (Tregs) [19] [20] [21] [22] , but Tregs and MDSCs are the most studied ones.
CD4 + FOXP3 + CD25 high Tregs seem to influence the local (intra tumor and stromal) recruitment of immunosuppressive cells [19] [20] [21] [22] . This occurrence becomes relevant in presence of Tregs increase with consequent negative prognostic impact, probably due to the negative influence on antitumor immune activation [23] [24] [25] . This is applicable to both immunogenic tumors such as kidney cancer [26] and melanoma [27] , as well as, to other cancers [20, 23, 25, 28] .
The myeloid-derived suppressor cells (MDSCs) [18, 29] , a CD11b + CD33 + CD14-HLA-DRhuman subpopulation cell, in basal conditions are poorly represented in the circulating stream and increase in presence of inflammatory, infectious, or neoplastic diseases. While in physiological conditions, the immature myeloid cells (IMCs) are stimulated to differentiation into mature macrophages, dendritic cells (DCs), or granulocytes, in the context of cancer, the release of mediators from the microenvironment and chemokines cause the formation of MDSC and their intratumor migration. They block migration of naıve CD62LC (L-selectin) T cells to lymphoid organs and induce intracellular pathways that promote self-expansion. They induce cell cycle arrest and decrease of T cell receptor (TCR) functionality through the production of high levels of arginase 1 (ARG-1) that depletes T cells of L-arginine and reactive oxygen and nitrogen species (ROS, RNS) from Th17 cells, respectively.
MDSCs release factors that stimulate regulatory conversion and expansion of Tregs also through the production of TGF-β and retinoic acid leading trans differentiation of Foxp3 regulatory T cells from monocyte-induced Th17 cells [30] . Furthermore MDSCs correlate with the tumor stage, prognosis, and resistance to treatment [31] . This knowledge allowed to reconsider the use of first-generation cytokines such as interleukin-2 (IL-2) and the development of new agents, such as anti-PD1 and anti-PDL1, which have recently revolutionized tumor treatment, especially in kidney cancer [32] and melanoma [33] , but also in lung [34] , bladder [35] , head and neck cancer [36] , and in other neoplasms [37, 38] .
IL-2 is a cytokine produced by activated T cells increase the proliferation and activation of cytotoxic T cells, natural killer (NK) cells and monocytes [39] . IL-2 is essential for the maintenance and expansion of immunosuppressive CD4 + CD25 + Tregs, in which IL7 2Rαβγ is constitutively expressed, to reduce the risk of an uncontrolled immune responses and autoimmunity [40] .
Food and Drug Administration (FDA) approval of IL-2 was obtained for treatment of patients with metastatic renal cancer (RCC) in 1992 and metastatic melanoma in 1998, after attaining an overall response of 16% in melanoma and 15% in RCC patients. It represents the only molecule capable of achieving long-term survival in < 10% of patients with melanoma and RCC. It can be used in different doses and modalities of administration but a high-dose bolus has been shown to be superior to other modalities only in patients attaining complete remission in renal cancer [41] . Furthermore, sporadic activity has been reported in other non immunogenic tumors [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] (Table 1) .
It is therefore possible to hypothesize that agents capable of negatively modifying these two immunosuppressive cell populations can improve the antitumor immune activity.
Immunomodulatory and chemotherapeutic agents active on Tregs include anti-CD25 mAb [54] , anti-CTLA-4 [55] , anti-GITR mAb [56] antibodies, and Gemcitabine (GEM) [57] , Cyclophosphamide (Cyt) [58] and Paclitaxel (P) respectively [59] .
Chemotherapy [57, 60] mostly Fluorouracil (FU) [60] and anti-angiogenetic molecules such as Sunitinib [61] and Bevacizumab [62] can reduce MDSCs, although it is difficult to measure this numerical and functional effect, considering also the rebound effect of MDSCs after Tregs reduction [63] . This phenomenon can be controlled by the simultaneous administration of Cyt and GEM [64] , probably due also to the dual action of GEM.
In light of the major efficacy of combination drugs [64] on both immune-suppressive cells and of the superiority of FU, over other agents, on MDSC [60] , we undertook a real-world experience with Cyt alone or in combination with FU, prior to the administration of IL-2, in heavily pre-treated solid tumor patients not susceptible to other potentially effective treatments.
The aim of this study was to evaluate the safety and feasibility of treatment, activity and the impact on the immune system (neutrophil 
Patients and methods
The study was made possible through the authorization of the competent institutions and after obtaining written informed consent from each patient in accordance with the Helsinki Declaration.
Eligibility criteria
The eligibility criteria required patients with advanced solid tumors, ECOG PS ≤ 1, previously treated, with adequate organ function (white blood cells ≥3 × 103/μL, neutrophil ≥1.5 × 103/μL, hemoglobin ≥10 g/dL, ALT/AST < 2.5 × UNV, bilirubin < 2.5 × UNV, left ventricular ejection fraction (LVEF) ≥50%, creatinine < 1.5 × UNV. Ineligibility criteria included ECOG PS > 1, the presence of clinically active brain metastases, recent cardiac illness, major infections, contraindications for the use of vasopressor drugs, and chronic steroid use.
Staging
Staging: brain/chest/abdominal computed tomography scan, electrocardiogram, echocardiography, hemochrome and chemistry, lymphocyte typing (CD3, CD4, CD8, Tregs, CD8/Treg, CD16, HLA-DR cells count), CRP, TSH, FT3, FT4. Lymphocyte typing was performed on a FACSCanto II system using FACSDiva software (BD Biosciences, Franklin Lakes, NJ, USA).
Before analysis, the flow cytometer settings were checked using compensation beads (CS&T beads, BD Bioscences) according to manufacturer's instructions. Multiparametric flow cytometry was performed on 50μL of sample stained for surface markers (10 μL for each monoclonal antibodies). Red blood cells were lysed with 2 mL of 1:5 diluted BD Pharm LyseTM lysing solution for 15 min at room temperature in darkness (10 mL of lysing solution in 40 mL of deionized water). The remaining cells were pelleted by centrifugation (1500 rpm for 5 min at room temperature), the supernatant was aspirated and the cell were resuspended in 500 μL of PBS. The following monoclonal antibodies (MoAb) were used: CD3 FITC, CD16 PE, CD4 PE-Cy7, CD8 APC-Cy7, CD45 PerCp, HLA-DR Horizon450, CD25 PE, CD127 PE-Cy7. All MoAb were purchased from BD Biosciences, excluding CD25 PE e CD127 PECy7 (Beckman Coulter, Miami, Florida, USA). The Treg was defined as CD3+/CD4+/CD25+/CD127-lymphocyte subpopulation.
Testing was repeated on days 1, 4, 7, 18 and at every other intravenous (I.V.) IL-2 therapy cycle, and after therapy cessation, and on day 1, every other cycle of subcutaneous (SC) administration of IL-2, and after therapy cessation.
Statistical considerations
Descriptive statistics included median and range as a measure of variability. The PFS and OS were computed by the Kaplan-Meier method, and Log-rank test was used to test the differences between subgroups. Differences were considered significant when P values were < 0.05.
Treatment
From February 2014, the therapy included Cyt 300 mg/sqm IV on Subsequently, the treatment was modified by adding FU 500 mg/ sqm I.V. bolus at day 1, followed by IL-2 I.V.C.I. regimen or IL-2 4.5 MUI S.C on days 3-6 and 17-20. The cycle was repeated on day 29. The treatment with Cyt-FU was performed as out-patient in both regimens while IL-2 I.V. and S.C was administered as in-patient and out-patient settings, respectively.
Responses were evaluated according to RECIST version 1.1 [65] , every 2 cycles, and therapy was continued in stable (SD) and responding (CR, PR) patients for other 4 cycles.
A dose reduction of IL-2 of 14 MUI/sqm was adopted in the case of renal, gastrointestinal or cardiovascular G2 toxicity and of 10 MUI/sqm for G3 cardiovascular toxicity. For G3 renal, pulmonary or greater than G1 sensory or motor neurological toxicity, the treatment was interrupted. No reduction in S.C. IL-2 for G2-3 toxicity was required, but in case of subjective intolerance or severe toxicity, the therapy was suspended.
Results
From February 2014 to January 2017 13/14 patients were treated ( Table 2) . Table 3 shows the toxicity, according to CTCAE v3.0 criteria [66] , reported during treatment. For six patients treated with 9 cycles (range 1-2) I.V. IL-2 administration, toxicity was manageable in the standard care unit. Grade 3 were represented by diarrhea in 2, proteinuria and erhytroderma G3 with hypereosinophilia in 1 patient, respectively. Vascular, gastrointestinal and general disorders treatment-related were reversible and side effects regressed upon discontinuation of therapy. Regarding other toxicities, proteinuria improved after 6 days from discontinuation therapy whereas hypothyroidism required continuous replacement therapy. Seventeen cycles (range 1-4) of S.C IL-2 were administered. Toxicity was mild although G3 toxicities as bleeding anemia was reported in 2 patients. The general disorders were mild with rapid improvement after treatment discontinuation. The hemorrhagic anemia resolved after transfusion of red blood cells, and it did not result in evident signs of bleeding at endoscopy. 
Toxicity

Response
Objective responses were observed in 2 PR, 1 HCC (Fig. 1A, B ) and 1 pancreatic carcinoma (PC) (Fig. 2A, B) patients treated with I.V. IL-2. They were previously treated with trans-arterial chemoembolization (TACE) and Sorafenib and with nab-Paclitaxel-Gemcitabine, radiotherapy and Oxaliplatin-Irinotecan-Capecitabine containing regimens respectively.
Moreover, a PR in a HCC patient, not subjected to TACE for portal vein thrombosis, was treated with IL-2 S.C (Fig. 3A, B) , after a progression to previous treatment with Sorafenib.
The pathological specimen of HCC patient treated with I.V. IL-2 showed moderately differentiated HCC with trabecular pattern, micronodular cirrhosis with severe lymphoyd infiltrate only in the portal space (Fig. 1C, D) with LCA positivity on micronodular cirrhosis at immunohistochemistry (Fig. 1E) . The post-treatment biopsy showed the presence of micronodular cirrhosis only (Fig. 1F) . The pathological specimen of HCC patient treated with S.C. IL-2 (Fig. 3C) showed well differentiated HCC with scattered lymphocyte T (CD3) infiltration (Fig. 3D) . Furthermore 3 SD (23%) and 7 PD (54%) were observed. Therefore, the overall response rate and disease control rate (PR + SD) were 23% and 46%, respectively (Table 4) . Noteworthy, these responder patient typologies are characterized by short-term, poor survival [67, 68] and are not susceptible for current effective treatment.
Furthermore, we observed a response on Ca-15-3, CEA, paraneoplastic hypercalcemia with renal insufficiency in breast cancer obtaining SD and on Ca-125 in non-responding ovarian cancer, as well as relevant subjective improvement in a gastro-intestinal stromal tumour (GIST) patient with mediastinal lymph node response and the stabilization of massive hepatomegaly.
The duration of response was 2+ and 3 months in the 2 HCC and 18+ months in PC patient. Pain control was obtained on 7/8 patients. The median progression-free survival and overall survival were 1 (range 1-8+) and 7 (range 1-20) months (Fig. 4A) . With the limits of the number of patients' cohort, differentiating by route of administration of IL-2, the median survival for S.C. and I.V. was 6 and 9 months, respectively (Fig. 4B) .
Regarding the hematological (Fig. 5A, B) and immunological parameters outcome (Fig. 5C, D) (Table 5) , although statistical considerations cannot be made for the small cohort of patients treated and the non-homogeneity of therapy, a relative stability in the neutrophils granulocytes, lymphocytes, monocytes, platelets and CD8 counts and an inverse relationship from the frequency of Plt and Tregs with a more marked Plt reduction with IL-2 I.V. and a more marked increase in Tregs with S.C. administration was observed, but without differences on survival (not shown).
The median variation from post-therapy to pre-therapy of CD8/Treg (Fig. 6A) , N/Ly (not shown) and Plt/Ly (Fig. 6B ) ratio in the S.C. and I.V IL-2 administration was −0.29, −0.23, 1 and 1, 0.59 and 0.70 respectively without a significant difference on survival as for pre-therapy Plt/Ly ratio (Fig. 6C) as for other parameters (not shown) in the overall group of patients treated Furthermore, in an early evaluation, during the first three weeks of treatment with IL-2 I.V. the lymphocyte subpopulations showed a bimodal pattern with a reduction at day 7 and an increase at days 4 and 18, except for CD16 and HLA-DR/CD3 cells (Table 6) (Fig. 7A, B) .
Therefore, given the even modest elevation of the total lymphocyte count after therapy, the variation of lymphocyte subpopulations and ratio can be considered real and Treg elevation after therapy is confirmed also by cD8/Treg reduction.
Finally, a reasonable reduction in CRP was observed after therapy in 5 patients (not shown)
Discussion
Immunotherapy is employed for a small group of tumors, with long- term results reported. However, immune surveillance plays an important role in the prognosis of all tumor types, even if it has no direct impact on conventional anticancer therapeutic agents.
Several parameters have been investigated to measure immune status, such as N/Ly [69] and Plt/Ly [70] . These parameters showed an impact on prognosis and survival and a predictive role in the response to chemotherapy in various neoplasms.
Recently, we have witnessed an explosion of immunotherapeutic research as anti-PD-1 and anti-PDL-1 inhibitors, which has led to confirmation of superiority over simple benchmark or standard treatments and has allowed an existing vacuum in some pathologies to be filled [32] [33] [34] [35] [36] .
There are handy, easily administered outpatient drugs, which provide long-term therapies (until progression or appearance of immunerelated side effects requiring expertise). While waiting to evaluate the impact of treatment with these new agents on survival in long-term follow-up, research on older immunotherapeutic agents with confirmed roles in RCC and melanoma related to long-term survival may be justified. The combined use of immunotherapeutic agents and other drugs could improve the therapeutic index and expand their use to a greater number of tumours.
IL-2, the main immunotherapeutic agent known in oncology, has these requirements and the direct induction of immunosuppression through Tregs and indirectly through MDSC expression can be modulated by Cyt (acting on Tregs) and by FU (the main suppressor of MDSCs). These antiblastic drugs could also play a role in antigenic priming, which may have synergistic action with immunotherapy.
This preliminary off-label experience in chemo-immunotherapy was undertaken by combining IL-2 with Cyt and FU in light of its theoretical, experimental and immunomodulating role. Both regimens can be considered safe and slightly and moderately toxic for S.C. and I.V. IL-2 administrations, respectively, in patients heavily pre-treated and chemo-resistant, such as PC, HCC [67, 68] and GIST, for which no therapeutic alternatives exist.
However, beyond the constant and transient capillary leak syndrome and other common toxicities, issues such as proteinuria, haemorrhagic anaemia, and skin rash with hypereosinophilia were reported. Proteinuria is an uncommon side effect during treatment with IL-2 [39] , which may in contrast exert a protective effect by increasing Tregs [71] . Hemorrhagic anemia is a side effect reported for a high-dose bolus of IL-2 [72] .
An extended skin rash, with intense itching and an increase of eosinophils was reported in a responsive PC patient. However, hyper eosinophilia correlates with an unfavorable prognosis and outcome in relation to immunotherapy [73] . Therefore, the relationship between nephropathic, cutaneous and haemorrhagic toxicity and a favorable response could be explained probably by the effect exerted by Cyt on Tregs, increasing the potential toxicity and activity of IL-2. No relationship between toxicity observed at previous treatment can be hypothesized, except bleeding anemia reported in two patients previously treated with Bevacizumab and Sorafenib, respectively.
Another issue to be considered is the possible interference of opioidbased antalgic therapy, in these heavily pre-treated patients, with the immune system [74] . The data are controversial with regard to the reduction of levels of IL-2 and other cytokines such as IL-6 and IL-10 [75] , while a negative influence on lymphocyte subpopulations has been reported without any significant influence on disease-free survival in patients submitted to radical surgery [76] .
Due to limitations of the type of experience and the small studied cohort of patients, we can only limit ourselves to a descriptive report of the potential reverting role of our regimens on immunosuppressive cells. A certain stability on the cellular blood series globally and an initial reduction of Treg followed by an increase at the end of treatment in the global population was observed. In addition, NK cells tended to increase and CD8/Treg and Plt/Ly ratio tended to decrease.
In the planned study of lymphocyte subpopulations during IL-2 I.V. a Treg increase on day 4, its decrease on day 7 followed by a rebound thereafter were observed.
From this preliminary experience definitive conclusions cannot be drawn due to the limits related to the non-homogeneity of the treatment and the scarce number of cases. However, we found a transient decrease of Treg after therapy, a subjective improvement, objective response on 23% of patients, and a reasonable lengthening in survival that represent a relevant aspect in an unfavorable patients population. Moreover, absence of intra-tumor lymphocyte infiltration pre-treatment in the two cases of HCC and the disappearance of tumor cells in the bioptic control after treatment with IL-2 I.V. were reported.
All these characteristics, in addition to the positive impact of IL-2, regardless of response, on survival corroborates our experiment and justifies further evaluation in the context of a prospective study.
Conclusion
This therapeutic combination is an attempt to engineer first-generation cytokine agent that will still play a role in cancer therapy even in the new era of check-point inhibitors.
However these preliminary data require further perspective study in a more selected series with the aim of verifying in a more timely manner the possible temporal variations of lymphocyte subpopulations by comparing chemo-immunotherapy with a control group with immunotherapy alone and its correlation with response to treatment and survival. /µL before and after therapy). (C): Overall survival according to basal P/Ly ratio Kaplan-Meier estimates of overall survival (OS) for basal PLT/Ly ratio < 150 (blue line) or > 150 (red line). Log-rank test: p = 0.1647, blue line: basal P/Ly : Platelets/Lymphocytes pre-therapy < 150; red line: P/Ly post: Platelets/Lymphocytes pre-therapy > 150.
Table 6
Quantitative variation of lymphocyte subpopulations during the first cycle of therapy with IL-2 i.v. compared to baseline values. 
